KRAS and hematologic disorder: In a comprehensive pan-cancer analysis by Lee et al., researchers examined the genomic landscape of Kirsten rat sarcoma viral oncogene homolog (KRAS)-altered solid and hematologic malignancies in 426,706 patients treated with chemotherapy, chemotherapy combined with ICIs, or ICI monotherapy [119].